| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034300 | GISKIT | Composition and method for medical imaging of body cavities |
Oct, 2030
(7 years from now) | |
| US9259494 | GISKIT | Composition and method for medical imaging of body cavities |
May, 2035
(11 years from now) | |
| US9849199 | GISKIT | Composition and method for medical imaging of body cavities |
Feb, 2036
(12 years from now) | |
Exem Foam Kit is owned by Giskit.
Exem Foam Kit contains Air Polymer-Type A.
Exem Foam Kit has a total of 3 drug patents out of which 0 drug patents have expired.
Exem Foam Kit was authorised for market use on 07 November, 2019.
Exem Foam Kit is available in foam;intrauterine dosage forms.
Exem Foam Kit can be used as use in sonohysterosalpinography to assess fallopian tube patency.
Drug patent challenges can be filed against Exem Foam Kit from 2023-11-08.
The generics of Exem Foam Kit are possible to be released after 11 February, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 7, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: 2023-11-08
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM;INTRAUTERINE
EXEM FOAM KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic